From the Editor ’s Desk…
Despite the large number of clinical trials on COVID-19 vaccines, only a few participants with pre-existing liver diseases were included. In this issue of the Journal, 2 separate studies analyse the safety and efficacy of COVID-19 vaccines in patients with non-alcoholic fatty liver disease (NAFLD) and in liver transplant recipients. Wang et al. reported that neutralising antibodies against SARS-CoV-were detected in 364 (95.5%) patients with NAFLD, based on an analysis of the CHESS2101 study from China.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Patrizia Burra, Frank Tacke, Vlad Ratziu, Stefan Zeuzem, Bruno Sangro, Paolo Angeli Tags: From the Editor's Desk Source Type: research